1 week Ago By Defense World Staff
Corebridge Financial Inc. reduced its position in Adaptive Biotechnologies Co. ( NASDAQ:ADPT – Free Report ) by 7.
0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,583 shares of the company’s stock after selling 4,347 shares during the period. Corebridge Financial Inc.
’s holdings in Adaptive Biotechnologies were worth $345,000 at the end of the most recent quarter. Several other hedge funds have also bought and sold shares of ADPT. Impact Partnership Wealth LLC lifted its stake in shares of Adaptive Biotechnologies by 8.
8% in the fourth quarter. Impact Partnership Wealth LLC now owns 19,078 shares of the company’s stock valued at $114,000 after buying an additional 1,539 shares in the last quarter. China Universal Asset Management Co.
Ltd. lifted its position in Adaptive Biotechnologies by 10.3% in the 4th quarter.
China Universal Asset Management Co. Ltd. now owns 31,292 shares of the company’s stock valued at $188,000 after acquiring an additional 2,928 shares in the last quarter.
Amundi lifted its position in Adaptive Biotechnologies by 41.2% in the 4th quarter. Amundi now owns 15,532 shares of the company’s stock valued at $93,000 after acquiring an additional 4,531 shares in the last quarter.
SG Americas Securities LLC boosted its stake in Adaptive Biotechnologies by 11.7% during the 4th quarter. SG Americas Securities LLC now owns 45,944 shares of the company’s stock valued at $275,000 after purchasing an additional 4,799 shares during the last quarter.
Finally, Rhumbline Advisers increased its holdings in Adaptive Biotechnologies by 3.0% during the 4th quarter. Rhumbline Advisers now owns 181,202 shares of the company’s stock worth $1,086,000 after purchasing an additional 5,361 shares in the last quarter.
Institutional investors and hedge funds own 99.17% of the company’s stock. Wall Street Analyst Weigh In Several brokerages recently issued reports on ADPT.
Piper Sandler reaffirmed an “overweight” rating and set a $11.00 target price (up previously from $7.00) on shares of Adaptive Biotechnologies in a research report on Thursday, February 20th.
BTIG Research lifted their price objective on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th.
Scotiabank increased their target price on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the company a “sector outperform” rating in a report on Thursday, February 13th.
Finally, The Goldman Sachs Group upgraded shares of Adaptive Biotechnologies from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $8.00 to $9.00 in a report on Friday, March 21st.
Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Buy” and a consensus price target of $9.40. Adaptive Biotechnologies Price Performance NASDAQ ADPT opened at $7.
72 on Friday. The business’s fifty day moving average is $7.90 and its 200-day moving average is $6.
60. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -7.
08 and a beta of 1.73. Adaptive Biotechnologies Co.
has a one year low of $2.28 and a one year high of $9.01.
Adaptive Biotechnologies ( NASDAQ:ADPT – Get Free Report ) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.
27) by $0.04. Adaptive Biotechnologies had a negative net margin of 89.
12% and a negative return on equity of 64.65%. During the same period last year, the business earned ($0.
30) EPS. Research analysts expect that Adaptive Biotechnologies Co. will post -0.
92 EPS for the current fiscal year. Insider Buying and Selling In related news, Director Peter M. Neupert sold 10,000 shares of the business’s stock in a transaction dated Monday, March 10th.
The stock was sold at an average price of $7.05, for a total value of $70,500.00.
Following the sale, the director now directly owns 224,690 shares in the company, valued at approximately $1,584,064.50. The trade was a 4.
26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink . Also, Director Robert Hershberg sold 53,000 shares of the stock in a transaction dated Wednesday, March 12th.
The stock was sold at an average price of $7.59, for a total transaction of $402,270.00.
Following the transaction, the director now owns 69,690 shares of the company’s stock, valued at $528,947.10. This represents a 43.
20 % decrease in their position. The disclosure for this sale can be found here . In the last quarter, insiders have sold 757,601 shares of company stock valued at $6,040,624.
6.20% of the stock is owned by company insiders. Adaptive Biotechnologies Profile ( Free Report ) Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. Featured Articles Five stocks we like better than Adaptive Biotechnologies When to Sell a Stock for Profit or Loss Joby Aviation: Operational Momentum vs. Market Sentiment How to Buy Cheap Stocks Step by Step Broadcom’s Big Outperformance Shows Strength Amid Tariff Decline NYSE Stocks Give Investors a Variety of Quality Options Carvana: Can Turnaround Strength Outdrive Market Headwinds? Want to see what other hedge funds are holding ADPT? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Adaptive Biotechnologies Co. ( NASDAQ:ADPT – Free Report ). Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.
com's FREE daily email newsletter ..
